Attention www.globalkeysolutions.net is now www.keypedia.com, read the full press release here.
KeyPedia LogoKeyPedia Icon
  1. Home
  2. /
  3. Records
  4. /
  5. 483
  6. /
  7. Premier Pharmacy Labs Inc
483
•Premier Pharmacy Labs Inc•May 9, 2014

Premier Pharmacy Labs Inc – FDA 483, May 9, 2014

Record Details

The FDA Form 483 details numerous deficiencies at a drug compounding facility. Key issues include the lack of validation for sterilization processes for drug products like Testosterone, Lidocaine, and Bupivacaine, and the absence of established procedures for preventing microbiological contamination. Aseptic techniques were not followed, with technicians failing to sanitize materials before placing them in the ISO 5 hood, and leaving uncapped vials open. Time dependency requirements for repackaging sterile drug products (e.g., Avastin) were not established.

Media fills were deficient, not accurately simulating production conditions, using inappropriate vial sizes, not demonstrating lengthy processes, lacking simulations for syringes/droppers, and not accounting for interruptions. Gowning procedures were unwritten and qualifications not conducted, leading to inconsistent practices such as inadequate apparel sizing, touching sterile garments with street clothes, and opening sterile bags before handwashing.

Environmental monitoring was inadequate, lacking dynamic active microbial air monitoring, non-viable particle monitoring, and daily personnel monitoring. Sterility testing was flawed; method suitability testing was not performed, raw data was recorded on unprotected spreadsheets by untrained staff, growth promotion testing used unsuitable strains, and positive controls were frequently negative. Sampling plans were not consistently followed, and scientific rationale for endotoxin testing was absent.

Aseptic processing areas lacked dynamic airflow pattern studies and continuous air pressure differential monitoring, with uncalibrated gauges. Cleaning and disinfection procedures were not assessed for efficacy, and sporicidal agents were not routinely used.

Company
Premier Pharmacy Labs Inc
Inspection date
May 9, 2014
Office
Florida District Office
Person
  • Michael H. Tollon (Approval Manager)
View Company Profile

ID · 75cfaa89-e35b-4d63-8925-734fd582c1ff

Violation Codes3
21 CFR 21021 CFR 211FD&C Act 801(a)(3)

Full citation text and observation details available on the Dashboard.

Other documents for Premier Pharmacy Labs Inc
  • WARNING_LETTER - 2014-05-09May 9, 2014

Your cart

Your cart is empty.

Browse public document pages and click Buy this document. We'll ask for your email at checkout, no account needed up front.

Browse documents

Discuss this record with AI

KeyPedia

ChatGPT

Claude

Perplexity

Grok

Copilot

Document or profile

One record shows the event. A profile shows the pattern.

Buy this document for the source file and details behind this single event.

Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.

Explore Premier Pharmacy Labs Inc
KeyPedia
Regulatory Data Transformed
Stay in the loop

KRA score changes, company updates and news. About monthly, unsubscribe anytime.

Contact
New York Office:
370 Jay Street 7th Floor
Brooklyn, NY 11201
Scranton Office:
Scranton Enterprise Center, Suite 217
201 Lackawanna Avenue
Scranton, PA, 18503
🇺🇸+1 917-789-5099
🇪🇺+48 532-447-507
info@keypedia.com
Quick Links
HomePlatform OverviewMedia
KeyPedia™ Lite
Browse HubDatabase DirectoryRecordsCompaniesOfficesPeopleCareersAbout UsFounding TeamMeet Our ExpertsPartners
Legal & Ethics
Privacy PolicyTerms of ServiceOur Values & MissionCode of Ethics & AI Policy
©2026 KeyPedia™ | Global Key Solutions Corp. All rights reserved.